Sentences with phrase «full duration of the program»

The retention rate of MOM program participants in the study was very high, and the researchers found few differences between the mothers who were and were not retained for the full duration of the program, except that mothers of boys were more likely to stay in the program.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Integrated Management of Childhood Illness (IMCI)- Part III - Chapter 11 - Breastfeeding Nutrient adequacy of exclusive breastfeeding for the term infant during the first six months of life (2002) Geneva, World Health Organization Full text [pdf 278kb] The optimal duration of exclusive breastfeeding: a systematic review Geneva, World Health Organization, 2001 Full text [pdf 1.06 Mb] Report of the expert consultation of the optimal duration of exclusive breastfeeding Report of an expert consultation Geneva, World Health Organization, 28 - 30 March 2001 Full text [pdf 122kb] The WHO Global Data Bank on Infant and Young Child Feeding Breastfeeding and Complementary Feeding Feeding Your Baby From Six Months To One Year Your guide to help you introduce food to your baby Adapted and reproduced with permission of Peel Public Health, Region of Peel A Practical Workbook to Protect, Promote and Support Breastfeeding in Community Based Projects Health Canada, Ottawa, 2002 This workbook is intended to assist the Canada Prenatal Nutrition Program (CPNP) or similar community based prenatal projects to identify strategies and specific actions to protect, promote and support breastfeeding in a population health context.

Whatever lab you choose, the program provides full funding for the duration of your time in the program, with highly competitive stipends and benefits.

Participants need only have the desire to embark on this life - long discipline, and commit their full attention to the study and practice of Hatha yoga for the duration of the 200hour YTT program.

Staff development is a key feature of the model; each site, in fact, has a full - time coordinator whose major responsibility is to conduct staff development sessions that initiate teachers into the SFA routines and sustain their continued use throughout the duration of the program.

To qualify, you or your spouse or common - law partner must be enrolled or committed to enrol as a full - time student in a qualifying education program of at least three months» duration at a designated educational institution.

SoFi's average lifetime savings methodology for its Employer Contribution Program assumes: 1) data entered during enrollment in the contribution program is accurate; 2) enrollees» interest rates do not change over time (PROJECTIONS FOR VARIABLE RATES ARE STATIC AT THE TIME OF REFINANCING AND DO NOT REFLECT ACTUAL MOVEMENT OF RATES IN THE FUTURE); 3) enrollees make all payments on time 4); enrollees make their minimum monthly payment for the full duration of their loan; 5) employer contribution is applied for the duration of the enrollee's loan; and 6) enrollee remains employed by the company for the duration of theiProgram assumes: 1) data entered during enrollment in the contribution program is accurate; 2) enrollees» interest rates do not change over time (PROJECTIONS FOR VARIABLE RATES ARE STATIC AT THE TIME OF REFINANCING AND DO NOT REFLECT ACTUAL MOVEMENT OF RATES IN THE FUTURE); 3) enrollees make all payments on time 4); enrollees make their minimum monthly payment for the full duration of their loan; 5) employer contribution is applied for the duration of the enrollee's loan; and 6) enrollee remains employed by the company for the duration of theiprogram is accurate; 2) enrollees» interest rates do not change over time (PROJECTIONS FOR VARIABLE RATES ARE STATIC AT THE TIME OF REFINANCING AND DO NOT REFLECT ACTUAL MOVEMENT OF RATES IN THE FUTURE); 3) enrollees make all payments on time 4); enrollees make their minimum monthly payment for the full duration of their loan; 5) employer contribution is applied for the duration of the enrollee's loan; and 6) enrollee remains employed by the company for the duration of their loaOF REFINANCING AND DO NOT REFLECT ACTUAL MOVEMENT OF RATES IN THE FUTURE); 3) enrollees make all payments on time 4); enrollees make their minimum monthly payment for the full duration of their loan; 5) employer contribution is applied for the duration of the enrollee's loan; and 6) enrollee remains employed by the company for the duration of their loaOF RATES IN THE FUTURE); 3) enrollees make all payments on time 4); enrollees make their minimum monthly payment for the full duration of their loan; 5) employer contribution is applied for the duration of the enrollee's loan; and 6) enrollee remains employed by the company for the duration of their loaof their loan; 5) employer contribution is applied for the duration of the enrollee's loan; and 6) enrollee remains employed by the company for the duration of their loaof the enrollee's loan; and 6) enrollee remains employed by the company for the duration of their loaof their loan.

Odyssey Tours and Safaris offer a full program of regular departures from two to seven days duration as well as private charters tours.

* Durations: Half day, Full Day and Extended (overnight) * Departures: Daily * Language speaking guides Tour Programs Half Day — 4 hrs City Sights Fashionista Style Tour Aboriginal Culture & Heritage Healesville Sanctuary Full Day — 7/8 hrs (flexible) Yarra Valley Dandenong Ranges / Yarra Valley / Healesville Sanctuary - combinations Mornington Peninsula Sovereign Hill and Ballarat Mt Macedon and the Spa Country Penguins and Koalas at Phillip Island Extended Great Ocean Road — 12 hours Cattlemen of «The High Country» — 12 hours (Fly / Drive combination saves 4 hours) Great Ocean Road / Grampians — two / three days Melbourne — Adelaide - Kangaroo Island Melbourne - Mildura — Mungo National Park 2 days / 3 nights Snow Skiing - Mt Buller Special Interest: Collectibles, Object d' Art, Art Jewellery, Antiquities, Indigenous artifacts — by appointment.

First visit will be tanjung Benoa beach for do the Bali Water Sports packages: banana boat, flyng fish, glass bottom boat and turtle island tour, is great water adventure you will have with full of fun, then we will having lunch Indonesian food, after lunch the tour program of Bali Tour Packages 7 Days and 6 Nights Tours will continue to visit the Garuda Wisnu Kencana to see the icon of Bali, inside you will see the biggest statue of god Vishnu and bird of Garuda, then the tour continue to visit Dream land beach, this beach is the famous beach for surfing and swimming activity, then we continue the trip to visit the Uluwatu temple or also known as the rock cliff temple, then we will watching kecak and fire dance near the temple, the duration of the dance is 1 hours with beautiful dancer and amazing story, then we continue the trip to jimbaran beach for having the delicious seafood dinner.

Artists have full access to their studios 24 hours a day, seven days a week; access to visiting artists, writers and curators; and receive a $ 500 monthly stipend for the duration of the program together with an initial $ 1500 materials allowance.

PARTICIPANTS ARE EXPECTED TO • Work full time in their VCU studios for the duration of the program.

Every iPhone Upgrade Program agreement comes with full AppleCare + for your iPhone for the duration (it's actually required as part of the plan).

Participation in their programs can be for the full duration of their homelessness or the school year.

The program has demonstrated remarkable gains with rapid improvements in developmental outcomes amongst the majority of the children who participated, with participation in the full 7 weeks yielding developmental advances equivalent to 6 months duration, as measured using Bayley scores.

The practicum should include at least 8 hours per month up to full - time employment, for the duration of the 22 month program, and should generate cases for case studies and peer - to - peer mentorship.

ABFT, however, is a 12 - week program; thus, it is only possible to test for differences in the outcomes for the waitlist control group with those of the ABFT group at six weeks, one - half of the full duration of ABFT.